NASDAQ: COLLCollegium Pharmaceutical Inc Stock
$29.97+0.10 (+0.33%)
Updated Dec 6, 2024
COLL Price
$29.97
Fair Value Price
$59.64
Market Cap
$966.54M
52 Week Low
$26.83
52 Week High
$42.29
P/E
11.06x
P/B
4.13x
P/S
2.08x
PEG
0.32x
Dividend Yield
N/A
Revenue
$599.25M
Earnings
$88.59M
Gross Margin
62.4%
Operating Margin
33.14%
Profit Margin
14.8%
Debt to Equity
5.98
Operating Cash Flow
$194M
Beta
0.9
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COLL Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COLL's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Value
B
Growth
D
Momentum
C
Sentiment
C
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
COLL
Ranked#11 of 65
Ranked#11 of 65
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $37.17 | A | |
| $23.21 | A | |
| $12.80 | A |
Be the first to know about important COLL news, forecast changes, insider trades & much more!
COLL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COLL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COLL ($29.97) is undervalued by 49.74% relative to our estimate of its Fair Value price of $59.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
COLL ($29.97) is significantly undervalued by 49.74% relative to our estimate of its Fair Value price of $59.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
COLL ($29.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COLL due diligence checks available for Premium users.
Valuation
COLL fair value
Fair Value of COLL stock based on Discounted Cash Flow (DCF)
Price
$29.97
Fair Value
$59.64
Undervalued by
49.74%
COLL ($29.97) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COLL ($29.97) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COLL ($29.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COLL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
11.06x
Industry
8.87x
Market
29.86x
COLL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
COLL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
COLL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.13x
Industry
2.29x
COLL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COLL price to earnings growth (PEG)
For valuing profitable companies with growth potential
COLL is good value based... subscribe to Premium to read more.
PEG Value Valuation
COLL's financial health
Profit margin
Revenue
$159.3M
Net Income
$9.3M
Profit Margin
5.9%
COLL's Earnings (EBIT) of $198.61M... subscribe to Premium to read more.
Interest Coverage Financials
COLL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$1.4B
Debt to equity
5.98
COLL's short-term liabilities ($459.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COLL's long-term liabilities ($941.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COLL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COLL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
-$249.0M
Financing
$149.0M
COLL's operating cash flow ($193.67M)... subscribe to Premium to read more.
Debt Coverage Financials
COLL vs Pharmaceutical Stocks
Collegium Pharmaceutical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.